Skip to main content
Equibles
COCH logo

COCH · Envoy Medical, Inc.

Track COCH — free

Use COCH with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.71 -0.02 (-2.75%) At close · Sep 4
Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Since inception, the Company has historically incurred negative operating cash flows and losses from operations as the Company advances the clinical development of its products and the funding process of clinical FDA trials. These matters raise substantial doubt about the Company's ability to continue as a going concern and although management has developed plans intended to support ongoing operations, such plans do not alleviate the substantial doubt.”
View the 10-Q filed Aug 10, 2026
Market Cap
$54.81M
Shares
77.19M

COCH metrics

58 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.71
Market cap
$54.81M

Price action

19 metrics
Price change (1W)
+2.9%
Price change (30D)
+4.3%
Price change (3M)
+7.4%
Price change (6M)
+9.1%
Price change (YTD)
+7.4%
Price change (1Y)
-47.4%
Trailing year
Price change (5Y)
-92.7%
52-week high
$1.59
52-week low
$0.39
Change from 52-week high
-55.3%
Change from 52-week low
+82.1%
Annualized volatility
150.4%
Beta
1.1
RSI (14D)
48.4
Price vs SMA 50
-0.7%
Price vs SMA 200
+1.3%
Avg volume (3M)
368,720
Relative volume
0.1
Average dollar volume
$257,419

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
77.19M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
256.9×
reciprocal yield 0.4%
P / book
16.1
reciprocal yield 6.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-44.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
-385.5%
Operating margin
-11,411.1%
Trailing 12 months
Net margin
-11,304.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$23.62M
Net income (TTM)
−$23.40M
Trailing 12 months
Diluted EPS (TTM)
$-0.77
FCF margin
—
Effective tax rate
41.9%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
-34.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$207,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+386.5%
Year over year · more shares
Revenue CAGR (3Y)
+0.6%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-708.5%
Return on assets
-97.7%
Debt / equity
—
Current ratio
1.7
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$19.68M
Latest balance sheet
Cash & equivalents
$19.68M
Total assets
$23.95M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$21.53M
Capital expenditures (TTM)
$179,000
R&D (TTM)
$14.03M
SG&A (TTM)
—
Stock compensation (TTM)
$804,000
R&D / revenue
6,776.3%
Stock compensation / revenue
388.4%

Ownership (13F)

3 metrics
13F filers
60
13F filer change QoQ
-5
Institutional ownership
29.8%

Short interest

3 metrics
Short interest
1.1%
Latest settlement · 5.6 days to cover
Days to cover
5.6d
Short-squeeze score
51 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1840877 CUSIP 29415V109 13F (30d) 26 filings 26 filers Visit website Investor relations